Almac meets evolving trial design with ‘on demand’ supply solution

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Yozayo)
(Image: Getty/Yozayo)

Related tags: Almac, Almac clinical services, Almac group, Trial supply management, Clinical supply, Clinical trial, Supply chain

In an aim to optimize the performance of changing clinical trials, Almac Clinical Services launched a supply chain solution – Almac Adapt – to provide sponsors with an adaptive supply strategy.

Almac Clinical Services, part of the Almac Group, said with the growth of biopharmaceutical development and clinical trials there has been an evolution in trial designs to match these targeted therapies that pose additional challenges.

 “The clinical trial landscape is experiencing rapid growth in biologics and personalized medicine. Our clients are faced with increasing challenges to overcome, which have resulted in aggressive study timelines, rising costs, the need for supply chain flexibility and the necessity to supply smaller, yet more global, clinical studies for specifically targeted populations,”​ an Almac spokesperson told us.

The new solution is a secondary packaging and labeling approach in which an operation is triggered by a distribution order and is sent directly to the patient or trial site.

The Almac spokesperson said the solution can reduce the supply cycle time to provide a ‘tighter control’ of supply including full late-stage customization of clinical supply kits to increase efficiency across the entire clinical supply chain.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars